{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:29:40Z","timestamp":1773289780952,"version":"3.50.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1007\/s11883-008-0063-6","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T07:01:10Z","timestamp":1224054070000},"page":"405-412","source":"Crossref","is-referenced-by-count":9,"title":["HDL therapy for cardiovascular diseases: the road to HDL mimetics"],"prefix":"10.1007","volume":"10","author":[{"given":"C. Roger","family":"White","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geeta","family":"Datta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenghao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himanshu","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Garber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod K.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayakonda N.","family":"Palgunachari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaila P.","family":"Handattu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjula","family":"Chaddha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. M.","family":"Anantharamaiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,16]]},"reference":[{"key":"63_CR1","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archinte.1981.00340090024008","volume":"141","author":"T. Gordon","year":"1981","unstructured":"Gordon T, Kannel WB, Castelli WP, Dawber TR: Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med 1981, 141:1128\u20131131.","journal-title":"Arch Intern Med"},{"key":"63_CR2","doi-asserted-by":"crossref","unstructured":"The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984, 251:365\u2013374.","DOI":"10.1001\/jama.1984.03340270043026"},{"key":"63_CR3","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S1359-6446(05)03514-2","volume":"10","author":"M.E. Brousseau","year":"2005","unstructured":"Brousseau ME: Emerging role of high-density lipoprotein in the prevention of cardiovascular disease. Drug Discovery Today 2005, 10:1095\u20131101.","journal-title":"Drug Discovery Today"},{"key":"63_CR4","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/ncpcardio0613","volume":"3","author":"S.D. Wiviott","year":"2006","unstructured":"Wiviott SD, Cannon CP: Update on lipid-lowering therapy and LDL-cholesterol targets. Nature Clin Pract Cardiovasc Med 2006, 3:424\u2013436.","journal-title":"Nature Clin Pract Cardiovasc Med"},{"issue":"SupplA","key":"63_CR5","first-page":"5A","volume":"4","author":"W.P. Castelli","year":"1988","unstructured":"Castelli WP: Cholesterol and lipids in the risk of coronary heart disease: the Framingham Heart Study. Can J Cardiol 1988, 4(Suppl A):5A\u201310A.","journal-title":"Can J Cardiol"},{"key":"63_CR6","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/01.ATV.18.9.1450","volume":"18","author":"D.T. Ashby","year":"1998","unstructured":"Ashby DT, Rye KA, Clay MA, et al.: Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol 1998, 18:1450\u20131455.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"63_CR7","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1161\/01.CIR.103.1.108","volume":"103","author":"G.W. Cockerill","year":"2001","unstructured":"Cockerill GW, Huehns TY, Weerasinghe A, et al.: Elevation of plasm a high-density lipoprotein concentration reduces interleukin-1 induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001, 103:108\u2013112.","journal-title":"Circulation"},{"key":"63_CR8","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0022-2275(20)33461-1","volume":"41","author":"M. Navab","year":"2000","unstructured":"Navab M, Hama SY, Cooke CJ, et al.: Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000, 41:1481\u20131494.","journal-title":"J Lipid Res"},{"key":"63_CR9","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0022-2275(20)33462-3","volume":"41","author":"M. Navab","year":"2000","unstructured":"Navab M, Hama SY, Anantharamaiah GM, et al.: Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 2 and 3. J Lipid Res 2000, 41:1495\u20131508.","journal-title":"J Lipid Res"},{"key":"63_CR10","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/01.RES.0000146094.59640.13","volume":"95","author":"P.J. Barter","year":"2004","unstructured":"Barter PJ, Nicholls S, Rye KA, et al.: Antiinflammatory properties of HDL. Circ Res 2004, 95:764\u2013772.","journal-title":"Circ Res"},{"key":"63_CR11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1046\/j.1365-2362.2002.00977.x","volume":"32","author":"B. Mackness","year":"2002","unstructured":"Mackness B, Durrington PN, Boulton AJ, et al.: Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest 2002, 32:259\u2013264.","journal-title":"Eur J Clin Invest"},{"key":"63_CR12","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1006\/bbrc.2001.6295","volume":"290","author":"M.N. Oda","year":"2002","unstructured":"Oda MN, Bielicki JK, Ho TT, et al.: Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem Biophys Res Commun 2002, 290:921\u2013927.","journal-title":"Biochem Biophys Res Commun"},{"key":"63_CR13","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/01.CIR.0000056523.08033.9F","volume":"107","author":"A. Mertens","year":"2003","unstructured":"Mertens A, Verhamme P, Bielicki JK, et al.: Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation 2003, 107:1640\u20131646.","journal-title":"Circulation"},{"key":"63_CR14","first-page":"27","volume":"14","author":"S.M. Sanguinetti","year":"2001","unstructured":"Sanguinetti SM, Brites FD, Fasulo V, et al.: HDL oxidability and its protective effect against LDL oxidation in type 2 diabetic patients. Diabetes Nutr Metab Clin Exper 2001, 14:27\u201336.","journal-title":"Diabetes Nutr Metab Clin Exper"},{"key":"63_CR15","first-page":"504","volume":"2","author":"M. Navab","year":"2006","unstructured":"Navab M, Anantharamaiah GM, Reddy ST, et al.: Mechanisms of disease: proatherogenic HDL\u2014an evolving field. Nature Clin Pract 2006, 2:504\u2013511.","journal-title":"Nature Clin Pract"},{"key":"63_CR16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tcm.2005.05.008","volume":"15","author":"M. Navab","year":"2005","unstructured":"Navab M, Anantharamaiah GM, Fogelman AM: The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med 2005, 15:158\u2013161.","journal-title":"Trends Cardiovasc Med"},{"key":"63_CR17","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1172\/JCI118345","volume":"96","author":"B.J. Lenten Van","year":"1995","unstructured":"Van Lenten BJ, Hama SY, de Beer FC, et al.: Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. J Clin Invest 1995, 96:2758\u20132767.","journal-title":"J Clin Invest"},{"key":"63_CR18","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/nm0904-902","volume":"10","author":"A.M. Fogelman","year":"2004","unstructured":"Fogelman AM: When good cholesterol goes bad. Nature Med 2004, 10:902\u2013903.","journal-title":"Nature Med"},{"key":"63_CR19","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1001\/jama.286.17.2136","volume":"286","author":"R. Zhang","year":"2001","unstructured":"Zhang R, Brennan ML, Fu X, et al.: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001, 286:2136\u20132142.","journal-title":"JAMA"},{"key":"63_CR20","doi-asserted-by":"crossref","first-page":"13032","DOI":"10.1073\/pnas.0405292101","volume":"101","author":"C. Bergt","year":"2004","unstructured":"Bergt C, Pennathur S, Fu X, et al.: The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A 2004, 101:13032\u201313037.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"63_CR21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s592-001-8074-z","volume":"38","author":"G. Ferretti","year":"2001","unstructured":"Ferretti G, Bacchetti T, Marchionni C, et al.: Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetologica 2001, 38:163\u2013169.","journal-title":"Acta Diabetologica"},{"key":"63_CR22","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1172\/JCI5286","volume":"103","author":"B. Lamarche","year":"1999","unstructured":"Lamarche B, Uffelman KD, Carpentier A, et al.: Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest 1999, 103:1191\u20131199.","journal-title":"J Clin Invest"},{"key":"63_CR23","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0022-2275(20)30115-2","volume":"43","author":"E. Boisfer","year":"2002","unstructured":"Boisfer E, Stengel D, Pastier D, et al.: Antioxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II. J Lipid Res 2002, 43:732\u2013741.","journal-title":"J Lipid Res"},{"key":"63_CR24","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1161\/01.CIR.0000103624.14436.4B","volume":"108","author":"B.J. Ansell","year":"2003","unstructured":"Ansell BJ, Navab M, Hama S, et al.: Inflammatory\/anti-inflammatory properties of high density lipoprotein distinguish patients from control subjects better than high density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003, 108:2751\u20132756.","journal-title":"Circulation"},{"key":"63_CR25","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1194\/jlr.M700138-JLR200","volume":"48","author":"B.J. Lenten Van","year":"2007","unstructured":"Van Lenten BJ, Wagner AC, Navab M, et al.: Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res 2007, 48:2344\u20132353.","journal-title":"J Lipid Res"},{"key":"63_CR26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.CIR.101.2.207","volume":"101","author":"D.J. Maron","year":"2000","unstructured":"Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 2000, 101:207\u2013213.","journal-title":"Circulation"},{"issue":"SupplC","key":"63_CR27","doi-asserted-by":"crossref","first-page":"C58","DOI":"10.1016\/j.ehjsup.2004.04.002","volume":"6","author":"M.J. Chapman","year":"2004","unstructured":"Chapman MJ: Are the effects of statins on HDL-cholesterol clinically relevant? Eur Heart J 2004, 6(Suppl C):C58\u2013C63.","journal-title":"Eur Heart J"},{"key":"63_CR28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0021-9150(99)00053-2","volume":"144","author":"J.R. Schaefer","year":"1999","unstructured":"Schaefer JR, Schweer H, Ikewaki K, et al.: Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 1999, 144:177\u2013184.","journal-title":"Atherosclerosis"},{"key":"63_CR29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/01.ATV.20.1.189","volume":"20","author":"M. Guerin","year":"2000","unstructured":"Guerin M, Lassel TS, Le Goff W, et al.: Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000, 20:189\u2013197.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"63_CR30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0033-0620(98)80010-8","volume":"41","author":"L.M. Belalcazar","year":"1998","unstructured":"Belalcazar LM, Ballantyne CM: Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol. Progress in Cardiovascular Disease 1998, 41:151\u2013174.","journal-title":"Progress in Cardiovascular Disease"},{"key":"63_CR31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0026-0495(86)90125-3","volume":"35","author":"A. Gnasso","year":"1985","unstructured":"Gnasso A, Lehner B, Haberbosch W, et al.: Effect of gemfibrozil on lipids, apoproteins, and postheparin lipolytic activities in normolipidemic subjects. Metabolism 1985, 35:387\u2013393.","journal-title":"Metabolism"},{"key":"63_CR32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1185\/030079903125001668","volume":"19","author":"A.S. Wierzbicki","year":"2003","unstructured":"Wierzbicki AS, Mikhailidis DP, Wray R, et al.: Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin 2003, 19:155\u2013168.","journal-title":"Curr Med Res Opin"},{"key":"63_CR33","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1053\/euhj.1999.2024","volume":"21","author":"H.B. Rubins","year":"2000","unstructured":"Rubins HB, Collins D, Robins SJ: The VA HDL intervention trial: clinical implications. Eur Heart J 2000, 21:1113\u20131115.","journal-title":"Eur Heart J"},{"key":"63_CR34","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s11886-003-0109-x","volume":"5","author":"S. Malik","year":"2003","unstructured":"Malik S, Kashyap ML: Niacin, lipids, and heart disease. Curr Cardiol Rep 2003, 5:470\u2013476.","journal-title":"Curr Cardiol Rep"},{"key":"63_CR35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","volume":"23","author":"P.J. Barter","year":"2003","unstructured":"Barter PJ, Brewer HB, Chapman MJ, et al.: Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:160\u2013167.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"63_CR36","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1194\/jlr.M600332-JLR200","volume":"48","author":"L.A. Morehouse","year":"2007","unstructured":"Morehouse LA, Sugarman ED, Bourassa PA, et al.: Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in NZW rabbits. J Lipid Res 2007, 48:1263\u20131272.","journal-title":"J Lipid Res"},{"key":"63_CR37","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJMoa031766","volume":"350","author":"M.E. Brousseau","year":"2004","unstructured":"Brousseau ME, Schaefer EJ, Wolfe ML, et al.: Effects of an inhibitor of cholestery ester transfer protein on HDL cholesterol. N Engl J Med 2004, 350:1505\u20131515.","journal-title":"N Engl J Med"},{"key":"63_CR38","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"P.J. Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, et al.: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109\u20132122.","journal-title":"N Engl J Med"},{"key":"63_CR39","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/0005-2795(70)90029-2","volume":"207","author":"R. Hirz","year":"1970","unstructured":"Hirz R, Scanu AM: Reassembly in vitro of a serum high density lipoprotein. Biochim Biophys Acta 1970, 207:364\u2013370.","journal-title":"Biochim Biophys Acta"},{"key":"63_CR40","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.100.6.594","volume":"100","author":"M. Eriksson","year":"1999","unstructured":"Eriksson M, Carlson LA, Miettinen TA, Angelin B: Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 1999, 100:594\u2013598.","journal-title":"Circulation"},{"key":"63_CR41","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1021\/bi011716p","volume":"41","author":"J.K. Bielicki","year":"2002","unstructured":"Bielicki JK, Oda MN: Apolipoprotein A-IMilano and apolipoprotein A-IParis exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry 2002, 41:2089\u20132096.","journal-title":"Biochemistry"},{"key":"63_CR42","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1161\/hc2501.092494","volume":"103","author":"P.K. Shah","year":"2001","unstructured":"Shah PK, Yano J, Reyes O, et al.: High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice: potential implications for acute plaque stabilization. Circulation 2001, 103:3047\u20133050.","journal-title":"Circulation"},{"key":"63_CR43","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","volume":"290","author":"S.E. Nissen","year":"2003","unstructured":"Nissen SE, Tsunoda T, Tuzcu EM, et al.: Effect of recombinant apoA-I milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292\u20132300.","journal-title":"JAMA"},{"key":"63_CR44","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0014-5793(74)80064-5","volume":"38","author":"J.P. Segrest","year":"1974","unstructured":"Segrest JP, Jackson RL, Morrisett JD, Gotto AM: A molecular theory of lipid-protein interactions in the plasma lipoproteins. FEBS Lett 1974, 38:247\u2013253.","journal-title":"FEBS Lett"},{"key":"63_CR45","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0065-3233(08)60643-9","volume":"45","author":"J.P. Segrest","year":"1994","unstructured":"Segrest JP, Garber DW, Brouillette CG, et al.: The amphipathic alpha helix: a multifunctional structural motif in plasma apolipoproteins. Adv Protein Chem 1994, 45:303\u2013369.","journal-title":"Adv Protein Chem"},{"key":"63_CR46","doi-asserted-by":"crossref","first-page":"12291","DOI":"10.1073\/pnas.94.23.12291","volume":"94","author":"D.W. Borhani","year":"1997","unstructured":"Borhani DW, Rogers DP, Engler JA, Brouillette CG: Crystal structure of truncated human apolipoprotein A-I suggests a lipid-boundconformation. Proc Natl Acad Sci U S A 1997, 94:12291\u201312296.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"63_CR47","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1073\/pnas.0506877103","volume":"103","author":"A.A. Ajees","year":"2006","unstructured":"Ajees AA, Anantharamaiah GM, Mishra VK, et al.: Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci USA 2006, 103:2126\u20132131.","journal-title":"Proc Natl Acad Sci USA"},{"key":"63_CR48","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1074\/jbc.M511475200","volume":"281","author":"V.K. Mishra","year":"2006","unstructured":"Mishra VK, Anantharamaiah GM, Segrest JP, et al.: Association of a model class A (apolipoprotein) amphipathic alpha helical peptide with lipid. J Biol Chem 2006, 281:6511\u20136519.","journal-title":"J Biol Chem"},{"key":"63_CR49","doi-asserted-by":"crossref","first-page":"10248","DOI":"10.1016\/S0021-9258(17)39238-4","volume":"260","author":"G.M. Anantharamaiah","year":"1985","unstructured":"Anantharamaiah GM, Jones JL, Brouillette CG, et al.: Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem 1985, 260:10248\u201310255.","journal-title":"J Biol Chem"},{"key":"63_CR50","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1172\/JCI117515","volume":"94","author":"A.J. Mendez","year":"1994","unstructured":"Mendez AJ, Anantharamaiah GM, Segrest JP, Oram JF: Synthetic amphipathic helical peptides that mimic apoliprotein A-I in clearing cellular cholesterol. J Clin Invest 1994, 94:1698\u20131705.","journal-title":"J Clin Invest"},{"key":"63_CR51","doi-asserted-by":"crossref","first-page":"9389","DOI":"10.1016\/S0021-9258(18)48092-1","volume":"262","author":"R.M. Epand","year":"1987","unstructured":"Epand RM, Gawish A, Iqbal M, et al.: Studies of synthetic peptide analogs of the amphipathic helix. Effect of charge distribution, hydrophobicity, and secondary structure on lipid association and lecithin:cholesterol acyltransferase activation. J Biol Chem 1987, 262:9389\u20139396.","journal-title":"J Biol Chem"},{"key":"63_CR52","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/prot.340150403","volume":"15","author":"Y.V. Venkatachalapathi","year":"1993","unstructured":"Venkatachalapathi YV, Phillips MC, Epand RM, et al.: Effect of end group blockage on the properties of a class A amphipathic helical peptide. Proteins 1993, 15:349\u2013359.","journal-title":"Proteins"},{"key":"63_CR53","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0022-2275(20)31599-6","volume":"42","author":"G. Datta","year":"2001","unstructured":"Datta G, Chaddha M, Hama S, et al.: Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res 2001, 42:1096\u20131104.","journal-title":"J Lipid Res"},{"key":"63_CR54","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0022-2275(20)31163-9","volume":"42","author":"D.W. Garber","year":"2001","unstructured":"Garber DW, Datta G, Chaddha M, et al.: A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res 2001, 42:545\u2013552.","journal-title":"J Lipid Res"},{"key":"63_CR55","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/hc0302.103711","volume":"105","author":"M. Navab","year":"2002","unstructured":"Navab M, Anantharamaiah GM, Hama S, et al.: Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002, 105:290\u2013292.","journal-title":"Circulation"},{"key":"63_CR56","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1161\/01.CIR.0000134275.90823.87","volume":"109","author":"M. Navab","year":"2004","unstructured":"Navab M, Anantharamaiah GM, Reddy ST, et al.: Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004, 109:3215\u20133220.","journal-title":"Circulation"},{"key":"63_CR57","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1161\/01.ATV.0000167412.98221.1a","volume":"25","author":"M. Navab","year":"2005","unstructured":"Navab M, Anantharamaiah GM, Hama S, et al.: D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005, 25:1426\u20131432.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"63_CR58","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1161\/CIRCULATIONAHA.104.517102","volume":"111","author":"A.L. Kruger","year":"2005","unstructured":"Kruger AL, Peterson S, Turkseven S, et al.: D-4F Induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes. Circulation 2005, 111:3126\u20133134.","journal-title":"Circulation"},{"key":"63_CR59","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1161\/01.CIR.0000070589.61860.A9","volume":"107","author":"J. Ou","year":"2003","unstructured":"Ou J, Ou Z, Jones DW, et al.: L-4F, an apolipoprotein A-I mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 2003, 107:2337\u20132341.","journal-title":"Circulation"},{"key":"63_CR60","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1021\/bi991209w","volume":"39","author":"G. Datta","year":"2000","unstructured":"Datta G, Chaddha M, Garber DW, et al.: The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry 2000, 39:213\u2013220.","journal-title":"Biochemistry"},{"key":"63_CR61","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1194\/jlr.M200157-JLR200","volume":"43","author":"M.L. Segall","year":"2002","unstructured":"Segall ML, Dhanasekaran P, Baldwin F, et al.: Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization. J Lipid Res 2002, 43:1688\u20131700.","journal-title":"J Lipid Res"},{"key":"63_CR62","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0022-2275(20)31620-5","volume":"42","author":"G. Datta","year":"2001","unstructured":"Datta G, Garber DW, Chung BH, et al.: Cationic domain 141\u2013150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo. J Lipid Res 2001, 42:959\u2013966.","journal-title":"J Lipid Res"},{"key":"63_CR63","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1161\/CIRCULATIONAHA.104.497107","volume":"111","author":"H. Gupta","year":"2005","unstructured":"Gupta H, White CR, Handattu S, et al.: An apolipoprotein E mimetic peptide dramatically lowers atherogenic lipoproteins and restores endothelial function in Watanabe heritable hyperlipidemic rabbits. Circulation 2005, 111:3112\u20133118.","journal-title":"Circulation"},{"key":"63_CR64","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1517\/13543784.15.1.13","volume":"15","author":"S.T. Reddy","year":"2006","unstructured":"Reddy ST, Anantharamaiah GM, Navab M, et al.: Oral amphipathic peptides as therapeutic agents. Expert Opin Investig Drugs 2006, 15:13\u201321.","journal-title":"Expert Opin Investig Drugs"},{"key":"63_CR65","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1161\/01.ATV.0000174589.70190.e2","volume":"25","author":"M. Navab","year":"2005","unstructured":"Navab M, Anantharamaiah GM, Reddy ST, et al.: An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005, 25:1932\u20131937.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"63_CR66","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1194\/jlr.P800003-JLR200","volume":"49","author":"L. Bloedon","year":"2008","unstructured":"Bloedon L, Dunbar R, Duffy D, et al.: Safety, pharmacokinetics and pharmacodynamics of a single dose of oral apolipoprotein A-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Research 2008, 49:1344\u20131352.","journal-title":"J Lipid Research"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-008-0063-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-008-0063-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-008-0063-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T14:01:50Z","timestamp":1631973710000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-008-0063-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["63"],"URL":"https:\/\/doi.org\/10.1007\/s11883-008-0063-6","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}